Highest-materiality recent filing
Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR
Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
Zai Lab Q4 total revenue $127.6M (+17% YoY); net loss narrows to $50.4M
Q4 product revenue $127.1M (+17% YoY); ZEJULA $56M (+16%), XACDURO $10.7M (+225%).
Zai Lab Q3 revenue up 14% to $116.1M; loss narrows; revises FY2025 guidance to at least $460M
Product revenue $115.4M (+13% YoY); VYVGART $27.7M, ZEJULA $42.4M, NUZYRA $15.4M.
Zai Lab Q2 revenue grows 9% YoY to $110M; operating loss improves 28%; targets Q4 profitability
Product revenue $109.1M (+9% YoY); VYVGART sales $26.5M (+46% QoQ); ZEJULA $41.0M (down from $45M YoY).
Zai Lab Q1 revenue up 22% to $106.5M; operating loss narrows 20%; on track for Q4 profitability
Product revenue $105.7M (+21% YoY); VYVGART $18.1M, ZEJULA $49.5M, NUZYRA $15.1M.
Zai Lab Q4 2024 revenue $109.1M (+66% YoY); guides FY2025 revenue $560-590M
Total revenues $399.0M for FY2024, up 50% YoY; product revenue $397.6M, up 49% YoY.
Zai Lab updates risks: employee medical fraud probes in China, Optune patent setbacks
Several current/former employees in ZEJULA sales team under criminal investigation by Chinese authorities for alleged medical insurance fraud; individuals detained or under compulsory measures.
Zai Lab Q3 net product revenue rises 47% YoY to $101.8M; KarXT bridging study positive
Net product revenue $101.8M, up 47% YoY; net loss $41.7M ($0.42/ADS loss).
Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M
Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.
On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.
Max materiality 0.80 · Median 0.65 · Most common event earnings